Clinical Trials for Glioblastoma
199 glioblastoma trials indexed, 79 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Glioblastoma
Glioblastoma is a type of brain tumor that originates in the glial cells, which support and protect neurons. It is classified as a grade IV astrocytoma, indicating it is the most aggressive form of brain cancer. The tumor grows rapidly and invades surrounding brain tissue, making it difficult to remove completely. Diagnosis usually involves a combination of neurological exams, imaging tests such as MRI or CT scans, and a biopsy to confirm the tumor type and grade.
Common symptoms of glioblastoma include persistent headaches, seizures, nausea, and changes in speech or vision. Patients may also experience weakness on one side of the body or difficulties with balance and coordination. The condition typically affects adults between the ages of 45 and 70, with a slightly higher incidence in males. Risk factors are not fully understood but may include exposure to high doses of radiation and certain genetic mutations.
Glioblastoma is a serious medical condition because of its rapid progression and poor prognosis. It accounts for about 15% of all primary brain tumors and has an incidence rate of approximately 3.2 cases per 100,000 people annually in the United States. The average survival time after diagnosis is about 15 months, despite treatment. The social impact is significant, with high healthcare costs and a substantial burden on families and caregivers due to the tumor’s aggressive nature and the need for ongoing care.
The Glioblastoma Treatment Landscape
The first-line treatment for glioblastoma typically involves surgery to remove as much of the tumor as possible, followed by radiation therapy combined with chemotherapy. The standard chemotherapy drug used is temozolomide, which is given during and after radiation. This approach aims to slow tumor growth and improve survival, although complete removal of the tumor is rarely possible due to its invasive nature. Treatment usually follows a carefully planned sequence to maximize effectiveness while managing side effects.
For patients whose tumors recur or do not respond well to first-line treatment, second- and third-line options include additional chemotherapy, targeted therapies, and experimental drugs. Some drug classes used are antiangiogenic agents, which aim to cut off the tumor’s blood supply, and immunotherapy drugs that try to boost the body's immune response against cancer cells. While options are available, none have shown consistent long-term success in extending survival beyond initial treatments.
Current treatments have limitations, including resistance to chemotherapy and radiation in some tumor subgroups. Side effects such as fatigue, nausea, and cognitive changes also affect quality of life. Research efforts focus on overcoming drug resistance, finding biomarkers to predict which patients will respond best to certain therapies, and developing treatments with fewer side effects. Addressing these gaps is critical to improving outcomes for glioblastoma patients.
Why Clinical Trials Matter for Glioblastoma
Clinical trials offer patients access to new treatments that are not yet widely available. Participating can provide closer medical monitoring and the chance to contribute to scientific knowledge that may help future patients. According to ClinicalTrials.gov, there are currently 199 glioblastoma clinical trials indexed, with 79 actively recruiting participants. This number reflects ongoing efforts to find better therapies and improve survival rates.
Joining a clinical trial also involves risks. Some treatments being tested may not work or could cause unexpected side effects. Trials may include placebo groups, meaning some participants receive standard care without the experimental treatment. Additional clinic visits and tests are often required, which can be time-consuming and physically demanding. Patients should carefully weigh these factors before enrolling.
The landscape of glioblastoma clinical trials includes studies sponsored by academic institutions, pharmaceutical companies, and cooperative research groups. These sponsors work together to design and run trials that meet regulatory standards and ethical guidelines. ClinicalTrials.gov serves as a centralized registry where patients, caregivers, and healthcare providers can find detailed information about trials, including eligibility criteria and locations, helping to connect patients with potential treatment options.
What to Look for in a Glioblastoma Clinical Trial
Clinical trials are divided into phases 1 through 4, each serving a different purpose. Phase 1 trials test the safety of a treatment and determine the right dose. Phase 2 trials evaluate how well the treatment works and continue to assess safety. Phase 3 trials compare the new treatment to the current standard care, and phase 4 trials happen after approval to monitor long-term effects. For glioblastoma, most trials are in Phase 1, with 80 studies. Phase 2 trials number 45, and there are 29 trials with no phase specified. Early Phase 1 trials account for 14 studies. This distribution shows many treatments are still in the early safety and dosing stages for glioblastoma.
Inclusion criteria are the rules that decide who can join a trial. For glioblastoma trials, common criteria include specific age ranges, often adults 18 years or older. Patients may need to have a confirmed diagnosis of glioblastoma and may have to meet certain biomarker or genetic test results. Prior treatments like surgery, radiation, or chemotherapy might be required or limited. Some trials look for patients at particular stages of the disease or with a certain duration since diagnosis. These criteria help ensure the study results apply to a similar group of patients and that the treatment is tested safely.
Exclusion criteria list conditions or factors that disqualify someone from joining. These often include other serious health problems, known as comorbidities, which could increase risks or interfere with the treatment. Some medications might interact badly with the trial drug, so patients taking those are excluded. Safety thresholds such as blood counts, liver, or kidney function tests must be met to reduce the chance of harm. Exclusion rules protect patients and help researchers get clear results without complications from other illnesses or treatments.
When considering a trial, patients should think about practical aspects. Trial length can vary from weeks to years, and visit schedules might require frequent trips to the study site. Travel distance and costs can be significant, so these should be discussed upfront. Patients should ask the research team questions like: What are the possible side effects? How will the treatment affect daily life? What happens if I want to stop the trial? Are there other treatment options outside the trial? Getting clear answers helps patients make informed decisions about joining a trial.
Primary Sources and Further Reading
To learn more about glioblastoma and clinical trials, it is helpful to consult trusted sources. These websites provide detailed information on brain tumors, cancer treatments, and ongoing research. They also offer guidance for patients and caregivers about what to expect during clinical trials and how to find studies that might be suitable.
- National Cancer Institute: Adult Glioblastoma Treatment
- MedlinePlus: Glioblastoma
- ClinicalTrials.gov: Glioblastoma Trials
- National Institute of Neurological Disorders and Stroke: Glioblastoma
Latest Research and Emerging Treatments for Glioblastoma (2026)
Current glioblastoma research is exploring several new treatment options to improve outcomes for patients. One Phase 3 trial is testing SonoCloud-9 combined with carboplatin chemotherapy in patients with recurrent glioblastoma (NCT05902169). SonoCloud-9 is a device that temporarily opens the blood-brain barrier, which usually blocks many drugs from reaching brain tumors. By allowing carboplatin to enter the brain more effectively, this approach aims to increase the chemotherapy’s impact on tumor cells. For patients, this could mean better drug delivery and potentially more effective control of tumor growth.
Another study is investigating the combination of the Optune device with temozolomide chemotherapy plus pembrolizumab immunotherapy in newly diagnosed glioblastoma patients (NCT06556563). Optune uses electrical fields to disrupt cancer cell division, while pembrolizumab helps the immune system recognize and attack tumor cells. This trial is testing whether adding immunotherapy to the existing treatment can extend survival. If successful, this glioblastoma new treatment 2026 could offer patients a way to strengthen their immune response alongside standard therapies.
Additional research includes a trial comparing targeted radiopharmaceutical therapy TLX101-Tx combined with lomustine chemotherapy against chemotherapy alone in recurrent glioblastoma (NCT07100730). TLX101-Tx delivers radiation directly to tumor cells, aiming to kill them more precisely while sparing healthy brain tissue. Another study is testing GammaTile radiation implants placed during surgery followed by standard radiation and chemotherapy (NCT07195591). These approaches focus on improving local control of the tumor after surgery. New drugs for glioblastoma and innovative radiation methods like these may help patients by increasing treatment effectiveness and potentially improving survival rates.
Frequently asked questions about Glioblastoma trials
How do I find Glioblastoma clinical trials?
The authoritative source for Glioblastoma clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 199 glioblastoma studies are currently indexed. You can search by entering "glioblastoma" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new glioblastoma trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Glioblastoma trials in?
Across the 199 glioblastoma trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Glioblastoma clinical trials are currently recruiting?
As of the latest scan, 79 glioblastoma trials have a "Recruiting" status on ClinicalTrials.gov, out of 199 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting glioblastoma trial matches their tracked condition.
Stay informed about glioblastoma research
Get a weekly briefing with the trials that matter most.